{"id":"https://openalex.org/W2424466908","doi":null,"title":"The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine.","display_name":"The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine.","alternate_titles":[],"publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2424466908","mag":"2424466908","pmid":"https://pubmed.ncbi.nlm.nih.gov/21415871"},"language":"en","primary_location":{"id":"pmid:21415871","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21415871","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Egyptian National Cancer Institute","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2424466908"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062818489","display_name":"Ebtesam Ahmad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I192398990","display_name":"Zagazig University","ror":"https://ror.org/053g6we49","country_code":"EG","type":"education","lineage":["https://openalex.org/I192398990"]}],"countries":["EG"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ebtesam I Ahmad","raw_affiliation_strings":["The Departments of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Departments of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt","institution_ids":["https://openalex.org/I192398990"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111695649","display_name":"Heba H. Gawish","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Heba H Gawish","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112172574","display_name":"Nashwa M. Alazizi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nashwa M A Al-Azizi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111822118","display_name":"Ashraf M Elhefni","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ashraf M El-Hefni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":6,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"21","issue":"4","first_page":"343","last_page":"350"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.9419999718666077},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/high-dose-cytarabine","display_name":"high-dose cytarabine","score":0.8500000238418579},{"id":"https://openalex.org/keywords/low-dose-cytarabine","display_name":"low-dose cytarabine","score":0.9549999833106995},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.890999972820282},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9139999747276306},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.9810000061988831},{"id":"https://openalex.org/keywords/m4-subtype","display_name":"M4 subtype","score":0.675000011920929},{"id":"https://openalex.org/keywords/inv-16","display_name":"inv(16)","score":0.9380000233650208},{"id":"https://openalex.org/keywords/adult-aml","display_name":"adult AML","score":0.5379999876022339},{"id":"https://openalex.org/keywords/ras-oncogene-activation","display_name":"ras oncogene activation","score":0.7059999704360962},{"id":"https://openalex.org/keywords/chromosomal-abnormalities","display_name":"chromosomal abnormalities","score":0.5799999833106995},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.5849999785423279},{"id":"https://openalex.org/keywords/npm1","display_name":"NPM1","score":0.6029999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8757611513137817},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.8360277414321899},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7252113223075867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7036240100860596},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5180511474609375},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.503692090511322},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4813274145126343},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4206704795360565}],"mesh":[],"locations_count":1,"locations":[{"id":"pmid:21415871","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21415871","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Egyptian National Cancer Institute","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1554413593","https://openalex.org/W1570936479","https://openalex.org/W1781943582","https://openalex.org/W1839310422","https://openalex.org/W1981125188","https://openalex.org/W2017349699","https://openalex.org/W2022164645","https://openalex.org/W2047626730","https://openalex.org/W2051864842","https://openalex.org/W2056960087","https://openalex.org/W2075091190","https://openalex.org/W2077365769","https://openalex.org/W2077544467","https://openalex.org/W2078481381","https://openalex.org/W2110721346","https://openalex.org/W2111486924","https://openalex.org/W2121371748","https://openalex.org/W2122051507","https://openalex.org/W2125676392","https://openalex.org/W2129465811","https://openalex.org/W2145954295","https://openalex.org/W2147839086","https://openalex.org/W2156911730","https://openalex.org/W2171383975","https://openalex.org/W2177396277","https://openalex.org/W2397107089"],"related_works":["https://openalex.org/W2120440386","https://openalex.org/W2227536142","https://openalex.org/W2561419248","https://openalex.org/W7128396242","https://openalex.org/W1570936479","https://openalex.org/W2076830250","https://openalex.org/W4303685213","https://openalex.org/W4296307075","https://openalex.org/W2171383975","https://openalex.org/W3159626057"],"abstract_inverted_index":{"UNLABELLED:":[0],"Activating":[1],"point":[2],"mutation":[3,130,377],"of":[4,19,24,48,62,70,98,110,170,213,241,389],"the":[5,25,45,57,68,145,176,187,263,283,286,363,396],"RAS":[6,195],"gene":[7,178,365],"has":[8],"been":[9],"generally":[10],"accepted":[11],"as":[12],"an":[13,381],"oncogenic":[14],"event":[15],"in":[16,30,65,74,79,149,175,182,203,224,252,285,295,362,407],"a":[17,94,108,168,239,312,333],"variety":[18],"malignancies.":[20,409],"It":[21],"represents":[22],"one":[23],"most":[26],"common":[27],"genetic":[28],"alterations":[29],"acute":[31],"myeloid":[32,416],"leukemia":[33,417],"(AML).":[34],"However":[35],"there":[36],"is":[37],"still":[38],"controversy":[39],"about":[40],"its":[41],"clinical":[42,118],"relevance":[43],"on":[44],"treatment":[46,385],"outcome":[47],"this":[49],"leukemia.":[50],"OBJECTIVE:":[51],"This":[52,280],"study":[53,87],"aimed":[54],"to":[55,67,116,144,206,227,332,403],"clarify":[56],"biologic":[58],"and":[59,128,158,215,258,302,347,387],"prognostic":[60],"impact":[61],"K-RAS":[63,129,177,364,412],"mutations":[64,361,401,413],"relation":[66],"dose":[69,147],"cytarabine":[71,369],"(ara-C)":[72],"used":[73,148],"post":[75],"induction":[76],"consolidation":[77,150],"chemotherapy":[78],"adult":[80,390],"AML":[81,91,214,358,391],"patients.":[82,392],"PATIENTS":[83],"AND":[84],"METHODS:":[85],"The":[86,135,210,233],"comprised":[88],"71de":[89],"novo":[90],"patients":[92,136,184,190,208,234,260,265,307,319,337,351,359],"with":[93,107,186,217,267,277,309,321,325,338,342,353],"male:":[95],"Female":[96],"ratio":[97],"1.4:":[99],"1;":[100],"their":[101],"ages":[102],"ranged":[103],"from":[104,329,367],"21-59":[105],"years":[106],"median":[109,240,348],"37":[111],"years.":[112,172],"They":[113,164],"were":[114,137,165,180,235],"subjected":[115],"full":[117],"evaluation,":[119],"routine":[120],"laboratory":[121],"investigations,":[122],"cytogenetic":[123],"studies":[124],"by":[125],"G":[126],"banding":[127],"detection":[131,378],"using":[132],"realtime":[133],"PCR.":[134],"randomized":[138],"into":[139],"2":[140],"groups":[141,304],"(gps)":[142],"according":[143],"ara-C":[146,157],"treatment,":[151],"HDAC":[152,310,330,343],"gp":[153,160],"receiving":[154,161],"400":[155],"mg":[156],"LDAC":[159,278,322,354],"100mg":[162],"ara-C.":[163],"followed":[166,236],"over":[167],"period":[169],"5":[171],"RESULTS:":[173],"Mutations":[174],"(mutRAS)":[179],"detected":[181],"23":[183],"(32%)":[185],"remaining":[188],"48":[189],"(68%)":[191],"having":[192],"wild":[193],"type":[194],"(wtRAS).":[196],"Blast":[197],"cell":[198],"percentage":[199],"was":[200,248,271,281,291],"significantly":[201,221,272],"lower":[202],"mutRAS":[204,225,257,264,301,318],"compared":[205,226],"wtRAS":[207,228,259,287,303,326,373],"(p\u22640.001).":[209],"M4":[211],"subtype":[212],"cases":[216],"Inv":[218],"16":[219],"showed":[220,344],"higher":[222,273,314,345,368],"frequencies":[223],"patients,":[229,374],"(p=0.015,":[230],"0.003,":[231],"respectively).":[232],"up":[237],"for":[238,384],"43":[242],"months":[243],"(range":[244],"11-57":[245],"months).":[246],"There":[247,290],"no":[249,292],"significant":[250,293],"difference":[251,294],"overall":[253],"survival":[254,298,388],"(OS)":[255],"between":[256,300],"(p=0.326).":[261],"Within":[262],"treated":[266,276,308,320,341,352],"HDAC,":[268],"cumulative":[269,315,346],"OS":[270],"than":[274,317,350,372],"those":[275,340],"(p=0.001).":[279,323],"not":[282],"case":[284],"group":[288],"(p=0.285).":[289],"disease":[296],"free":[297],"(DFS)":[299],"(p=0.923).":[305],"MutRAS":[306],"had":[311],"statistically":[313],"DFS":[316,349],"Patients":[324],"also":[327],"benefited":[328],"but":[331],"lesser":[334],"extent.":[335],"Among":[336],"wtRAS,":[339],"(p=0.031).":[355],"CONCLUSION:":[356],"Adult":[357],"carrying":[360],"benefit":[366],"doses":[370],"more":[371,404],"so":[375],"pretreatment":[376],"could":[379],"be":[380],"important":[382],"predictor":[383],"strategy":[386],"These":[393],"findings":[394],"counter":[395],"prevailing":[397],"bias":[398],"that":[399],"oncogene":[400],"lead":[402],"aggressive":[405],"behavior":[406],"human":[408],"KEY":[410],"WORDS:":[411],"-":[414,418],"Acute":[415],"Cytarabine.":[419]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2424466908","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
